Skip to content

Medical Topic

Neck Pain and Bioresonance: Randomized Double-Blind Rayocomp Study

Randomized double-blind Rayocomp study in neck pain; NDI and VAS outcomes, sponsor report, study design, and clinical interpretation.

Preliminary evidence

Short answerA Germany-registered study evaluating the Rayocomp bioresonance device in cervical spine syndrome was designed as a randomized, prospective, double-blind, and placebo-controlled trial. Registered in the German Clinical Trials Register under the number DRKS00017381, the final sample size of the study is recorded as 54 individuals. In the final clinical report published by the sponsor, significant improvements in the Neck Disability Index and various pain measurements were reported in the active device group compared to placebo. However, the primary source of the results is the manufacturer/sponsor clinical report; the availability of an independent peer-reviewed full-article publication would further increase the strength of the evidence.

Why is the study notable?

One of the most frequently criticized issues in the bioresonance literature is the lack of a sham device and a double-blind design. In this regard, this study has a stronger design: patient and practitioner/investigator blinding, a non-functional placebo device, and pre-defined objective/standardized endpoints were used.

Design of the study

According to the DRKS registry, the study was conducted in adults with at least moderate pain in the cervical region. Participants were allocated to 10 active Rayocomp sessions or 10 placebo sessions within 21 days. The primary endpoint was the Neck Disability Index (NDI), while secondary endpoints were VAS pain scores, SF-36 quality of life, and safety.

In the registry, the target sample size is reported as 52, and the final sample size as 54. The study was completed in 2019.

What results are in the final clinical report?

In the final clinical study report published by Rayonex, a significant improvement in the NDI in the active device group and no marked change in the placebo group were reported. Significant changes in favor of the active group were also reported in VAS parameters such as neck pain, headache, back pain, shoulder pain, and cervical tension.

Why do we interpret the results cautiously?

Although the study design appears strong, the outcome report was published by the manufacturer/sponsor. The publication of the full dataset, detailed statistical analysis, protocol deviations, and lost follow-ups in an independent peer-reviewed journal allows for a better assessment of the reliability of the results. Therefore, neither ignoring the data nor presenting it as definitive evidence is appropriate.

The potential role of bioresonance in neck pain

In cervical pain, the aim is not only to reduce the pain score, but also to improve range of motion, daily function, sleep, headache burden, and analgesic requirements. When bioresonance is chosen, following up with NDI, VAS, and functional measures is scientifically more meaningful.

When is a standard evaluation necessary?

If there is loss of strength in the arm or hand, progressive numbness, gait impairment, trauma, fever, a history of cancer, severe night pain, or changes in bladder-bowel control, a standard neurological/orthopedic evaluation is primarily required. In mechanical neck pain, exercise, ergonomics, manual/physical therapy, and appropriate pharmacological approaches are the foundational options.

Our approach in our Bodrum clinic

In neck pain, we first distinguish the mechanical, neurological, and myofascial components. If bioresonance is deemed appropriate, we integrate it with exercise and other pain treatments; at baseline and follow-up, we record pain, mobility, and daily functional measures.

Pain Treatment →   |   Bioresonance →

References

  1. German Clinical Trials Register. DRKS00017381. Randomized, prospective, double-blind study in cervical spine disorder. DRKS registry
  2. Rayonex Biomedical. Final Clinical Study Report, R-HWS, Version 1.2, 20 February 2020. Final report

Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 11, 2026

Medical editorial information

This content has been medically reviewed and approved by Dr. Kerem Çağlayan. It is intended for general education and does not replace an individual diagnosis or treatment plan.